// App-Quantinova.ai

: Nivolumab demonstrates benefit over nomogram-predicted 12-month survival as salvage therapy for metastatic urothelial carcinoma.

Researchers

Presenter

  • Gregory Russell Pond

Principal Investigators

  • Guru Sonpavde

  • Matt D. Galsky

  • Padmanee Sharma

  • Jonathan E. Rosenberg

  • Toni K. Choueiri

  • Joaquim Bellmunt

  • Jae-Lyun Lee

  • Soon Il Lee

  • Alex Azrilevich

  • Shuo Yang

  • Kyna McCullough Gooden

  • Dean F. Bajorin

Medical Centers

  • McMaster University, Hamilton, ON, Canada

  • Dana-Farber Cancer Institute, Boston, MA

  • Icahn School of Medicine at Mount Sinai/Tisch Cancer Institute, New York, NY

  • 1.MD Anderson Cancer Center, Houston, TX

  • Memorial Sloan Kettering Cancer Center, Port Washington, NY

  • Dana-Farber-Cancer Institute, Brigham and Women's Hospital, and Harvard Medical School, Boston, MA

  • Harvard Medical School and Dana-Farber Cancer Institute, Boston, MA

  • University of Ulsan College of Medicine, Asan Medical Center, Seoul, Korea

  • Dankook University Hospital, Dankook University College of Medicine, Cheonan, Korea, Republic of (South)

  • Bristol-Myers Sqiubb, Princeton, NJ

Locations

  • Canada

  • United States

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

  • Nephrology

Disease

  • N/A

Biomarkers

  • N/A

Drug/Treatment

  • Nivolumab

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • NCT02387996

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved